Recent developments in the chemistry of bicyclic 6-6 systems: Chemistry of pyrido[1,2-c]pyrimidines

References

• (a) Elattar, K. M.; Abozeid, M. A.; Mousa, I. A.; El-Mekabaty, A. Advances in 1,2,4-triazepines chemistry. RSC Adv. 2015, 5, 106710–106753. doi:10.1039/C5RA21108E; (b) Elattar, K. M.; Youssef, I.; Fadda, A. A. Reactivity of indolizines in organic synthesis. Synth. Commun. 2016, doi:10.1080/00397911.2016.1166252.
   Web of Science ®Google Scholar
• Elattar, K. M.; Abozeid, M. A.; Etman, H. A. Developments in 1,2,5-triazepines chemistry: Reactions and synthetic applications. Synth. Commun. 2016, 46, 93–117. doi:10.1080/00397911.2015.1109126.
   Web of Science ®Google Scholar
• Fadda, A. A.; Abdel-Galil, E.; Elattar, K. M. Chemistry of 3-oxo-n-(pyridin-2-yl)butanamide and related compounds. Synth. Commun. 2015, 45 (18), 2053–2082.
   Web of Science ®Google Scholar
• Fadda, A. A.; Elattar, K. M. Reactivity of dehydroacetic acid in organic synthesis. Synth. Commun. 2016, 46, 1–30. doi:10.1080/00397911.2015.1092549.
   Web of Science ®Google Scholar
• Fadda, A. A.; El-Hadidy, S. A.; Elattar, K. M. Advances in 1,8-naphthyridines chemistry. Synth. Commun. 2015, 45 (24), 2765–2801.
   Web of Science ®Google Scholar
• Fadda, A. A.; Bayoumy, N. M.; Elattar, K. M. Recent progress in the chemistry of 2-tosylacetonitrile. Synth. Commun. 2015, 45 (23), 2637–2675.
   Web of Science ®Google Scholar
• Fadda, A. A.; Elattar, K. M. Utility of enaminonitriles in heterocyclic synthesis: Synthesis of some new azepine, azocine, and pyrroldione derivatives. J. Heterocycl. Chem., 2014, 51 (6), 1697–1704.
   Web of Science ®Google Scholar
• Fadda, A. A.; El-Mekabaty, A.; Mousa, I. A.; Elattar, K. M. Chemistry of 3-(1H-indol-3-yl)-3-oxopropanenitrile. Synth. Commun. 2014, 44 (11), 1579–1599.
   Web of Science ®Google Scholar
• Fadda, A. A.; El-Mekabaty, A.; Elattar, K. M. Chemistry of enaminonitriles of pyrano[2,3-c]pyrazole and related compounds. Synth. Commun. 2013, 43 (20), 2685–2719.
   Web of Science ®Google Scholar
• Gouda, M. A.; Berghot, M. A.; Abd El-Ghani, G. E.; Elattar, K. M.; Khalil, A. M. Chemistry of 2-aminothiophene-3-carboxamide and related compounds. Turk. J. Chem. 2011, 35, 815–837.
   Web of Science ®Google Scholar
• Gouda, M. A.; Abu-Hashem, A. A.; Saad, H. H.; Elattar, K. M. 5-Chloropyrazole-4-carboxaldehydes as synthon in heterocyclic synthesis. Res. Chem. Intermed. 2016, 42, 2119–2162. doi:10.1007/s11164–015-2139–6.
   Web of Science ®Google Scholar
• Ko, S. S.; Batt, D. A.; Bertrand, M. B.; Delucca, G. V.; Langevine, C. M.; Liu, Q.; Srivastava, A. S.; Watterson, S. H. Preparation of 4-phenylcarbazole-1-carboxamide compounds useful as Bruton’s tyrosine kinase (Btk) inhibitors. WO PCT Int. Appl. 2014210087 A1 20141231, 2014.
   Google Scholar
• Shiromizu, I.; Kato, K.; Yamamoto, I.; Hamamoto, H. Novel PARP inhibitor. US Patent Appl. 2006/0004028, 2006; Chem. Abstr. 2006, 144, 108339.
   Google Scholar
• Wolska, I.; Herold, F.; Maj, M. 4-(2-Pyridyl)-1H,2H-pyrido[1,2-c]pyrimidine-1,3-dione. Acta Cryst. 2003, E59, o511–o513.
   Google Scholar
• Pisklal, M.; Herold, F.; Anulewicz-Ostrowska, R.; Wawer, I. Structural studies of 4-aryloctahydro-pyrido[1,2-c]pyrimidine derivatives. J. Mol. Struct. 2002, 605, 85–92.
   Web of Science ®Google Scholar
• Herold, F.; Maciejewska, D.; Wolska, I. Dimers of solid 4-arylhexahydro-1H,3H-pyrido[1,2-c]pyrimidine-1,3-diones: 13C CP/MAS NMR, x-ray diffraction, and semi-empirical MO studies. J. Phys. Org. Chem. 2000, 13, 213–220.
   Web of Science ®Google Scholar
• Maciejewska, D.; Herold, F.; Wolska, I. Structure of 4-(4-methoxyphenyl)hexahydro-1H,3H-pyrido[1,2-c]pyrimidine in the solid state. J. Mol. Struct. 2000, 553, 73–77.
   Web of Science ®Google Scholar
• Wolskaa, I.; Herold, F. Crystal and molecular structure of 4-arylhexahydro-1H,3H-pyrido[1,2-c]pyrimidine-1,3-dione derivatives. Z. Naturforsch. 2002, 57b, 1315–1319.
   Google Scholar
• Maciejewska, D.; Zołek, T.; Herold, F. CoMFA methodology in structure–activity analysis of hexahydro- and octahydropyrido[1,2-c]pyrimidine derivatives based on affinity towards 5-HT1A, 5-HT2A, and a1-adrenergic receptors. J. Mol. Graphics Model. 2006, 25, 353–362.
   PubMed Web of Science ®Google Scholar
• Pisklak, M.; Krol, M.; Herold, F.; Wolska, I.; Wawer, I. Structural studies of pyrido[1,2-c]pyrimidine derivatives by 13C CPMAS NMR, x-ray diffraction, and GIAO/DFT calculations. J. Mol. Struct. 2008, 892, 325–330.
   Web of Science ®Google Scholar
• Goteti, K.; Brassil, P. J.; Good, S. S.; Garner, C. E. Estimation of human drug clearance using multiexponential technique. J. Clin. Pharmacol. 2008, 48, 1226–1236.
   PubMed Web of Science ®Google Scholar
• Mahmood, I. Role of fixed coefficients and exponents in the prediction of human drug clearance: How accurate are the predictions from one or two species? J. Pharm. Sci. 2009, 98, 2472–2493.
   PubMed Web of Science ®Google Scholar
• Berellini, G.; Springer, C.; Waters, N. J.; Lombardo, F. In silico prediction of volume of distribution in human using linear and nonlinear models on a 669 compound data set. J. Med. Chem. 2009, 52, 4488–4495.
   PubMed Web of Science ®Google Scholar
• Von Korff, M.; Freyss, J.; Sander, T. Flexophore, a new versatile 3D pharmacophore descriptor that considers molecular flexibility. J. Chem. Inf. Model. 2008, 48, 797–810.
   PubMed Web of Science ®Google Scholar
• Huang, J. J.; Huang, Y. J.; Zhu, L.; Yuan, M.; Huang, L. Design, synthesis, and alpha1-adrenoreceptor blocking activity of new arylpiperazines containing acetophenone substituents. Pharmazie 2014, 69 (8), 578–584.
   PubMed Web of Science ®Google Scholar
• Ulenberg, S.; Belka, M.; Król, M.; Herold, F.; Hewelt-Belka, W.; Kot-Wasik, A.; Bączek, T. Prediction of overall in vitro microsomal stability of drug candidates based on molecular modeling and support vector machines: Case study of novel arylpiperazines derivatives. PLoS One 2015, 10 (3), e0122772/1–e0122772/16.
   PubMed Web of Science ®Google Scholar
• Markey, M. D.; Kelly, T. R. Troubleshooting a molecular motor: A remarkably stable N-acyl pyridinium salt. Tetrahedron, 2008, 64, 8381–8388.
   Web of Science ®Google Scholar
• Uchida, T.; Rodriquez, M.; Schreiber, S. L. Skeletally diverse small molecules using a build/couple/pair strategy. Org. Lett. 2009, 11, 1559–1562.
   PubMed Web of Science ®Google Scholar
• Vovk, M. V.; Lebed, P. S. Zh. Obshch. Farmat. Khim. 2005, 3 (2), 43.
   Google Scholar
• Yadav, L. D. S.; Rai, A.; Rai, V. K.; Awasthi, C. Biorenewable resources in the Biginelli reaction: Cerium(III)-catalyzed synthesis of novel iminosugar-annulated perhydropyrimidines. Synlett 2007, 12, 1905–1908.
   Web of Science ®Google Scholar
• Yadav, L. D. S.; Rai, A. The first mineral-catalyzed one-pot [3 + 1+2] coupling protocol for multifunctionalized fused-ring pyrimidines. Synthesis 2009, 16, 2802–2808.
   Web of Science ®Google Scholar
• Donghi, M.; Ferrara, M.; Koch, U.; Narjes, F.; Ontoria Ontoria, J. M.; Summa, V. WO PCT Int. Appl. 2007/028789, 2007; Chem. Abstr. 2007, 146, 316932.
   Google Scholar
• Lebid, P. S.; Vovk, M. V. Zh. Obshch. Farmat. Khim. 2008, 6 (1), 51.
   Google Scholar
• Kheder, N. A.; Mabkhot, Y. N.; Farag, A. M. Synthesis and antimicrobial evaluation of some new pyrimidine derivatives. Heterocycles 2008, 75, 887–897.
   Web of Science ®Google Scholar
• Rosen, J. D.; German, N.; Kerns, R. J. Efficient synthesis of the 2-amino-6-chloro-4-cyclopropyl-7-fluoro-5-methoxy-pyrido[1,2-c]pyrimidine-1,3-dione core ring system. Tetrahedron Lett. 2009, 50, 785–789.
   PubMed Web of Science ®Google Scholar
• Lebed, P. S.; Vashchuk, A. V.; Rusanov, E. B.; Vovk, M. V. Zh. Obshch. Farmat. Khim. 2007, 5 (1), 61.
   Google Scholar
• Bartolome-Nebreda, J. M.; Garcıa-Lopez, M. T.; Gonzalez-Mun, R.; Cenarruzabeitia, E.; Latorre, M.; Del Rıo, J.; Herranz, R. 5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK1 receptor antagonists: Structure–activity relationship studies on the central 1,3-dioxoperhydropyrido[1,2-c]pyrimidine scaffold. J. Med. Chem. 2001, 44, 4196–4206.
   PubMed Web of Science ®Google Scholar
• Herold, F.; Kleps, J.; Wolska, I.; Nowak, G. Synthesis of new hexahydro- and octahydropyrido[1,2-c]pyrimidine derivatives with an arylpiperazine moiety as ligands for 5-HT1A and 5-HT2A receptors. Farmaco 2002, 57, 959–971.
   PubMedGoogle Scholar
• Herold, F.; Król, M.; Kleps, J. Synthesis of new hexahydro- and octahydropyrido[1,2-c]pyrimidine derivatives with an arylpiperazine moiety as ligands for 5-HT1A and 5-HT2A receptors, part III. Acta Pol. Pharm. 2004, 61 (2), 139–150.
   PubMedGoogle Scholar
• Herold, F.; Król, M.; Kleps, J.; Nowak, G. Synthesis of new hexahydro and octahydropyrido[1,2-c]pyrimidine derivatives with an arylpiperazine moiety as ligands for 5-HT1A and 5-HT2A receptors, part 4. Eur. J. Med. Chem. 2006, 41, 125–134.
   PubMed Web of Science ®Google Scholar
• Herold, F.; Chodkowski, A.; Izbicki, Ł.; Król, M.; Kleps, J.; Turło, J.; Nowak, G.; Stachowicz, K.; Dybała, M.; Siwek, A. Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity, part 1. Eur. J. Med. Chem. 2009, 44, 1710–1717.
   PubMed Web of Science ®Google Scholar
• Chodkowski, A.; Wrobel, M. Z.; Turło, J.; Kleps, J.; Siwek, A.; Nowak, G.; Belka, M.; Baczek, T.; Mazurek, A. P.; Herold, F. Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity, part 4. Eur. J. Med. Chem. 2015, 90, 21–32.
   PubMed Web of Science ®Google Scholar
• Herold, F.; Chodkowski, A.; Izbicki, Ł.; Turło, J.; Dawidowski, M.; Kleps, J.; Nowak, G.; Stachowicz, K.; Dybała, M.; Siwek, A.; Mazurek, A. P.; Mazurek, A.; Pluciński, F. Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity, part 3. Eur. J. Med. Chem. 2011, 46, 142–149.
   PubMed Web of Science ®Google Scholar
• Herold, F. Izbicki, Ł.; Chodkowski, A.; Dawidowski, M.; Król, M.; Kleps, J.; Turło, J.; Wolska, I.; Nowak, G.; Stachowicz, K.; Dybała, M.; Siwek, A.; Nowak, M.; Pieniążek, E.; Jarończyk, M.; Sylte, I.; Mazurek, A. P. Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity, part 2. Eur. J. Med. Chem. 2009, 44, 4702–4715.
   PubMed Web of Science ®Google Scholar
• Gomołka, A.; Ciesielska, A.; Wrobel, M. Z.; Chodkowski, A.; Kleps, J.; Dawidowski, M.; Siwek, A.; Wolak, M.; Stachowicz, K.; Sławinska, A.; Nowak, G.; Satała, G.; Bojarski, A. J.; Belka, M.; Ulenberg, S.; Baczek, T.; Skowronek, P.; Turło, J.; Herold, F. Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity, part 5. Eur. J. Med. Chem. 2015, 98, 221–236.
   PubMed Web of Science ®Google Scholar
• Kim, R. M.; Liu, J.; Gao, X.; Boga, S. B.; Guiadeen, D.; Kozlowski, J. A.; Yu, W.; Anand, R.; Yu, Y.; Selyutin, O. B.; et al. Preparation of bicyclic heterocycles as Btk inhibitors for therapy. U.S. Pat. Appl. Publ. 20140206681 A1 20140724, 2014.
   Google Scholar
• Vovk, M. V.; Lebed, P. S. Zh. Obshch. Farmat. Khim. 2005, 3 (4), 57.
   Google Scholar
• Natarajan, S. R.; Chen, M.-H.; Heller, S. T.; Tynebor, R. M.; Crawford, E. M.; Minxiang, C.; Kaizheng, H.; Dong, J.; Hu, B.; Hao, W.; Chen, S.-H. Synthesis of the 2H-quinolizin-2-one scaffold via a stepwise acylation–intramolecular annulation strategy. Tetrahedron Lett. 2006, 47, 5063–5067.
   Web of Science ®Google Scholar
• Molina, P.; Aller, E.; Lorenzo, Á.; López-Cremades, P.; Rioja, I.; Ubeda, A.; Terencio, M. C.; Alcaraz, M. J. Solid-phase synthesis and inhibitory effects of some pyrido[1,2-c]pyrimidine derivatives on leukocyte functions and experimental inflammation. J. Med. Chem. 2001, 44, 1011–1014.
   PubMed Web of Science ®Google Scholar